Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure

NCT03721744 is registered in ClinicalTrials.gov with 1Globe Health Institute LLC as lead sponsor.

NCT NCT03721744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03721744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure
Lead sponsor
1Globe Health Institute LLC
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 25, 2018
Completion date
September 30, 2025
Enrollment
336 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer